Citable filing context
ELV's research view summarizes recent SEC filing context, starting with earnings from Jul 15, 2026.
| Filed | Item | Context |
|---|---|---|
| Jul 15, 2026 | earnings | Elevance Health reported Q2 2026 operating revenue of $49.8 billion and raised its full-year 2026 adjusted EPS guidance. |
| Jun 10, 2026 | guidance_update | Elevance Health reaffirmed FY 2026 earnings guidance of at least $19.85 per diluted share and 90.2% benefit expense ratio. |
| May 13, 2026 | management_change | Elevance Health shareholders elected directors and approved executive compensation at the Annual Meeting on May 13, 2026. |
| Jul 15, 2026 | Guidance: adjusted_diluted_eps | 27.00 to not reported |
| Jul 15, 2026 | Guidance: diluted_eps | 20.10 to not reported |
| Jul 15, 2026 | Guidance: operating_cash_flow | 6.00 to not reported |
| Jul 15, 2026 | mda_quarterly | Elevance Health reported a 16.1% decline in second-quarter 2026 shareholders’ net income, driven by elevated medical cost trends in Medicaid and Medicare, alongside a loss contingency accrual related to historical Medicare Advantage risk adjustment data. While total operating revenue grew 0.8% to $49.8 billion, fueled by premium rate increases and CarelonRx growth, overall profitability was pressured by higher benefit expenses and increased operating costs. The company’s medical membership declined 1.5% year-over-year, primarily due to Medicaid eligibility redeterminations and deliberate repositioning within the Medicare Advantage segment. Management is addressing these headwinds through the 2026-2027 Operating Model Transformation Program, which aims to streamline organizational structures and accelerate AI adoption. Regulatory pressures remain significant, with the OBBBA legislation and new pharmacy benefit manager reforms impacting long-term operations. Despite these challenges, Elevance maintains a strong liquidity position, with $38.8 billion in cash and investments and a debt-to-capital ratio of 40.8%. The company successfully resolved a CMS enforcement matter regarding historical risk adjustment data in July 2026. Looking forward, the company continues to focus on medical management programs, provider network optimization, and the expansion of its Carelon specialty care and behavioral health capabilities to mitigate ongoing cost volatility. |
| Apr 22, 2026 | mda_quarterly | Elevance Health reported a 1.5% increase in total operating revenue to $49.49 billion for Q1 2026, driven by premium rate increases in Health Benefits and growth in CarelonRx product revenues, despite membership attrition. However, shareholders' net income decreased 19.2% to $1.76 billion, with EPS falling 16.8% to $8.00, primarily due to decreased operating gain across all segments and increased interest expense, partially offset by favorable financial instrument and investment income. Operating cash flow significantly improved to $4.33 billion due to favorable working capital. Total medical membership declined 0.9% to 45.4 million, mainly from Medicaid redeterminations and decreases in Medicare Advantage, Employer Group Risk-Based, and Federal Employee Program, partially offset by growth in Employer Group Fee-Based. Medical cost trends remain elevated, particularly in Medicaid due to higher acuity and utilization, and in Individual ACA following Medicaid redetermination shifts. The company faces regulatory impacts from the OBBBA, including PBM reforms and Medicaid changes, and the expiration of enhanced ACA Premium Tax Credits, which may affect Individual market enrollment. CMS issued an intent to impose sanctions for Medicare Advantage risk adjustment data noncompliance, with a compliance deadline extended to July 31, 2026. The Provider Settlement Agreement in the BCBSA Antitrust Litigation became effective in September 2025, with a $666 million payment recognized in September 2024. Elevance Health is implementing a 2026-2027 Operating Model Transformation Program to streamline operations and enhance technology. The company maintains a strong liquidity position with $38.19 billion in cash and investments and a stable 42.0% debt-to-capital ratio. |
Source: SEC EDGAR filing text and events; period Jul 15, 2026; filed Jul 15, 2026.
ELV company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.